Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Pacific Biosciences (PACB)
NASDAQ:PACB
Holding PACB?
Track your performance easily
PACB Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.16 - $10.65
Previous Close$1.96
Volume8.14M
Average Volume (3M)9.73M
Market Cap
$536.77M
Enterprise Value$986.38M
Total Cash (Recent Filing)$471.15M
Total Debt (Recent Filing)$920.75M
Price to Earnings (P/E)―
Beta2.56
Next Earnings
Feb 13, 2025EPS Estimate
-$0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.46
Shares Outstanding273,863,544
10 Day Avg. Volume10,242,004
30 Day Avg. Volume9,728,630
Standard Deviation0.27
R-Squared0.14
Alpha-0.00506
Financial Highlights & Ratios
Price to Book (P/B)1.19
Price to Sales (P/S)3.10
Price to Cash Flow (P/CF)-3.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue5.70
Enterprise Value/Gross Profit18.69
Enterprise Value/Ebitda-3.78
Forecast
1Y Price Target
$3.07Price Target Upside49.76% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
Pacific Biosciences News
PremiumCompany Announcements
Pacific Biosciences Updates Executive Severance Agreements
PremiumCompany Announcements
Pacific Biosciences Appoints CEO as Interim CFO
Bulls Say, Bears Say
Bulls Say
Debt ManagementPacBio's refinancing of a portion of its convertible debt addresses investor concerns related to the company's debt overhang.
Market ExpansionA record number of Onso units were shipped, including two-thirds to new customers, which supports growth into the future.
Product LaunchNew SPRQ chemistry and Vega benchtop long read instrument have needle-moving potential for Pacific Biosciences.
Bears Say
Financial PerformanceThe company's total revenue of $40.0 million was lower than estimates and represented a 28% year-over-year decrease.
Guidance And ExpectationsRevio pushouts and macro headwinds weigh on the quarter, resulting in lower guidance to reflect capex pressure and a longer sales cycle following the Vega launch.
Product CompetitionCannibalization with Revio remains the key question, as the Vega platform will likely be of interest to labs that would consider purchasing a Revio platform.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
PACB FAQ
What was Pacific Biosciences’s price range in the past 12 months?
Pacific Biosciences lowest stock price was $1.16 and its highest was $10.65 in the past 12 months.
What is Pacific Biosciences’s market cap?
Currently, no data Available
When is Pacific Biosciences’s upcoming earnings report date?
Pacific Biosciences’s upcoming earnings report date is Feb 13, 2025 which is in 53 days.
How were Pacific Biosciences’s earnings last quarter?
Pacific Biosciences released its earnings results on Nov 07, 2024. The company reported -$0.22 earnings per share for the quarter, beating the consensus estimate of -$0.221 by $0.001.
Is Pacific Biosciences overvalued?
According to Wall Street analysts Pacific Biosciences’s price is currently Undervalued.
Does Pacific Biosciences pay dividends?
Pacific Biosciences does not currently pay dividends.
What is Pacific Biosciences’s EPS estimate?
Pacific Biosciences’s EPS estimate is -$0.21.
How many shares outstanding does Pacific Biosciences have?
Pacific Biosciences has 273,863,560 shares outstanding.
What happened to Pacific Biosciences’s price movement after its last earnings report?
Pacific Biosciences reported an EPS of -$0.22 in its last earnings report, beating expectations of -$0.221. Following the earnings report the stock price went down -6.122%.
Which hedge fund is a major shareholder of Pacific Biosciences?
Among the largest hedge funds holding Pacific Biosciences’s share is ARK Investment Management LLC. It holds Pacific Biosciences’s shares valued at 57M.
---
Pacific Biosciences Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$3.07 (49.76% Upside)
$3.07 (49.76% Upside)
Blogger Sentiment
Neutral
PACB Sentiment 50%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 926.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $172.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.4%
Last 30 Days ▲ 13.0%
Last 30 Days ▲ 13.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-77.87%
12-Months-Change
Fundamentals
Return on Equity
-64.80%
Trailing 12-Months
Asset Growth
-23.62%
Trailing 12-Months
Company Description
Pacific Biosciences
Pacific Biosciences of California, Inc. engages in the development, manufacture and sale of an integrated platform for genetic analysis. Its products and services include PacBio sequel system, consumables, analytical software, and single molecule real-time (SMRT) compatible products. It operates through the following geographical segments: North America, Europe, and Asia Pacific. The company was founded by Stephen Turner and Joseph Vincent Bonventre on July 14, 2000 and is headquartered in Menlo Park, CA.
---
PACB Company Deck
---
PACB Earnings Call
Q3 2024
0:00 / 0:00
---
PACB Stock 12 Month Forecast
Average Price Target
$3.07
▲(49.76% Upside)
Technical Analysis
Best Analysts Covering PACB
1 Year
1 Year Success Rate
7/18 ratings generated profit
1 Year Average Return
+17.01%
reiterated a buy rating 2 months ago
Copying Kyle Mikson CFA's trades and holding each position for 1 Year would result in 38.89% of your transactions generating a profit, with an average return of +17.01% per trade.
---